CSF2 and neoplasm: The first FDA-approved OV, Talimogene Laherparepvec (T-VEC), encodes GM-CSF, which enhances antigen-presenting cell (APC) recruitment, therefore promoting tumor-specific T cell responses against cutaneous melanomas [102,103] (Figure 6).